This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Astellas Pharma (ALPMF) Receives a Hold from UBS
UBS analyst maintained a Hold rating on Astellas Pharma today and set a price target of Yen2,600.00.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The word on The Street in general, suggests a Hold analyst consensus rating for Astellas Pharma with a Yen2,404.50 average price target.
The company has a one-year high of Yen2,717.00 and a one-year low of Yen1,314.00. Currently, Astellas Pharma has an average volume of 6.95M.
Read More on ALPMF:
Disclaimer & DisclosureReport an Issue
- Astellas’ Menopause Drug Fezolinetant Hits Key Safety Milestone in Japan
- Astellas Highlights R&D Strategy While Flagging Market and Development Risks
- Astellas and HOVON Phase 3 AML Trial for Xospata Misses Survival Goal
- Astellas Flags Risks and Uncertainties Around Sustainability Plans and Pipeline
- Why Is Vir Biotechnology Stock Up Today?
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
